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Abstract
The outcome of solid organ transplantation has improved significantly in the past few decades
with the advent of cyclosporine and other newer immunosuppressive agents including tacrolimus,
mycophenolate mofetil, interleukin-2 receptor blockers, and rapamycin. A prominent consequence
of the development in posttransplant immunosuppressive regimens is the reduced incidence of
acute rejections, from 30% to 40% to approximately 15% or even lower (Gjertson, Clin T ranspl
2000:467-80), although it still remains an important risk factor compromising long-term renal allograft
survival. The acute and chronic nephrotoxicity of immunosuppressive agents, notably calcineurin
inhibitors, have attracted increasing attention, and the reduction of these untoward effects has
constituted an important theme of clinical research in transplantation. The current knowledge on
the spectrum and mechanisms of nephrotoxicity pertinent to immunosuppressive agents used in
renal transplantation is reviewed in this article and possible strategies for prevention or amelioration
of the nephrotoxicity; the future directions for investigations are also discussed.
Key words: Cyclosporine/therapeutic use, Immunosuppression, Survival rate, Transforming growth factor-
beta/metabolism
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R E V I E W
A R T I C L E
INTRODUCTION
The outcome of solid organ transplantation has improved
significantly in the past few decades with the advent of
cyclosporine and other new immunosuppressive agents.
For renal transplantation, the combined use of
corticosteroid and cyclosporine with or without
azathioprine has been the conventional prophylactic
immunosuppressive therapy until recent years, when
tacrolimus, mycophenolate mofetil, interleukin (IL)-2
receptor blockers, and lately, rapamycin, have been
increasingly included. Consequently, the use of
polyclonal or monoclonal anti-T lymphocyte antibodies
has decreased accordingly. A prominent consequence of
the development in posttransplant immunosuppressive
regimens is the reduced incidence of acute rejections,
from 30% to 40% to approximately 15% or even lower
(1). Recent cohort and registry data suggest that the
improvement in short-term renal allograft survival
observed with new immunosuppressive regimens could
lead to prolongation of long-term graft survival, although
66
Nephrotoxicity in renal transplant
Tacrolimus has a dose-related diabetogenic potential, but
is less prone to induce gum hypertrophy or hirsutism,
and may be associated with a lower risk or severity of
hypertension and hyperlipidemia compared with
cyclosporine, although the data could be confounded by
the drug levels targeted in the studies (3). Calcineurin
inhibitors have significantly decreased the risk of acute
rejection in the early posttransplant period and improved
the short-term survival of renal allografts. Although they
still have a central role in prophylactic immuno-
suppressive protocols, novel treatment regimens free of
calcineurin inhibitors are being investigated, with the aim
of obviating their nephrotoxic effect, the monitoring and
the early detection of which may not be easy.
Clinicopathological manifestations
Nephrotoxicity of calcineurin inhibitors can be acute or
chronic (Fig. 1). Acute toxicity is dose-related, and is
related to afferent arteriolar vasoconstriction, leading to
decreased glomerular filtration rate and acute
deterioration of renal function. Accordingly, this
functional, hemodynamically mediated acute toxicity is
reversible upon dosage reduction. Acute tubular
dysfunction is another common side effect, manifesting
as various electrolyte and acid-base disturbances,
attributed to perturbed tubular transport at the distal parts
of the nephron (4). Hyperkalemia, metabolic acidosis,
hypomagnesemia, and hyperuricemia are often seen.
Treatment with sodium bicarbonate is effective in
correcting hyperkalemia and acidosis, and helps to reduce
the adverse effect of acidosis on bone metabolism (5).
to a lesser extent. In this context, acute rejection remains
an important risk factor compromising long-term renal
allograft survival. The acute and chronic nephrotoxicity
of immunosuppressive agents, notably calcineurin
inhibitors, have thus attracted increasing attention, and
the reduction of these untoward effects has constituted
an important theme of clinical research in transplantation.
The current knowledge on the spectrum and mechanisms
of nephrotoxicity pertinent to immunosuppressive agents
used in renal transplantation is reviewed in this article.
Based on these data, possible strategies for prevention
or amelioration of the nephrotoxicity, and the future
directions for investigations, are also discussed.
CALCINEURIN INHIBITORS
Cyclosporine and tacrolimus represent the two calcineurin
inhibitors currently used in renal transplantation. Cyclo-
sporine A is a hydrophobic cyclic peptide produced by
the fungus Tolypocladium inflatum gams (2). After
entering the cell, cyclosporine will bind to a cytosolic
immunophilins, cyclophilin 18 or 40, and this complex
will inhibit the action of calcineurin, which is a
phosphatase important in intracellular signal transduction.
Inhibition of calcineurin will reduce the transcription of
cytokine, in particular IL-2, which has a pivotal role in
acute graft rejection. Tacrolimus has a similar mechanism
of action, except that it binds to another immunophilins,
FK-binding protein 12, 13, or 59, instead of cyclophilin
in the cytoplasm. The side-effect profiles of cyclosporine
and tacrolimus are similar, and include nephrotoxicity,
neurotoxicity, hypertension, and hyperlipidemia.
Figure 1. Manifestations of cyclosporine nephrotoxicity.
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Hypomagnesemia is usually mild and a magnesium
supplement is seldom needed. In contrast, chronic
nephrotoxicity is associated with irreversible structural
changes (Fig. 2), notably striped tubulointerstitial fibrosis
beginning in the outer medulla and progressing into
the medullary rays of the cortex, tubular atrophy,
characteristic degenerative hyaline changes in the
arteriolar wall, especially afferent arterioles, sometimes
resulting in obliterative arteriolopathy, and glomerular
sclerosis or collapse. It is often progressive, and its
relationship with blood levels of the calcineurin inhibitor
is more obscure. The relationship between acute and
chronic nephrotoxicity induced by calcineurin inhibitors
remains to be defined. In addition, the relative
contribution of immunologic and nonimmunologic
mechanisms leading to chronic allograft dysfunction is
being investigated.
Thrombotic microangiopathy (TMP) represents a distinct
form of acute vascular toxicity of cyclosporine, which
can affect the graft kidney. It is a rare but serious
complication, often presenting with acute deterioration
of renal function in association with thrombocytopenia
and hemolytic anemia. The clinical manifestations
resemble thrombotic thrombocytopenic purpura and
hemolytic uremic syndrome. The pathogenesis involves
endothelial damage induced by cyclosporine, with the
consequent release of cytokines, platelet activation, and
the formation of microthrombi. It is associated with a
high risk of early graft loss, and is potentially life-
threatening. Withdrawal of cyclosporine is the mainstay
of treatment. Plasmapheresis and intravenous
immunoglobulin have been reported to confer benefit
(6). Although subsequent resumption of cyclosporine has
been observed without recurrence of TMP (7), it is
advisable to convert to tacrolimus if a calcineurin
inhibitor is deemed necessary (8,9). It should be noted
that TMP has also been reported with tacrolimus (10,
11). With the availability of alternative agents such as
mycophenolate mofetil and rapamycin, it may therefore
be safer to consider avoidance of all calcineurin inhibitors
in patients with a history of TMP.
Mediators of acute or chronic nephrotoxicity
induced by calcineurin inhibitors
Acute nephrotoxicity often occurs during the early
months after transplantation, when relatively higher
target blood levels of calcineurin inhibitors were aimed
for, and thus needs to be differentiated from other causes
of acute graft dysfunction, especially acute rejection.
Various mechanisms have been proposed to explain the
intrarenal vasoconstriction (12), including altered
expression of thromboxanes and prostaglandins,
endothelin, nitric oxide (NO), changes in intracellular
calcium concentration, changes in the rennin-angiotensin
system, sympathetic over-drive, and increased oxidative
stress with free-radical production. It is probable that a
multitude of mechanisms contribute toward an excessive
vasoconstrictor effect. Nevertheless, careful monitoring
to avoid excessively high blood levels remains the most
important preventive measure. However, overexpression
of transforming growth factor (TGF)-β1, over-activity
of the renin-angiotensin system, and increased deposition
of matrix proteins are prominent abnormalities observed
in chronic nephrotoxicity.
Thromboxanes, which are derived from prostaglandins,
cause vasoconstriction and platelet aggregation.
Prostaglandins also mediate vascular tone and may be
vasoconstrictors or vasodilators depending on its
subtypes. Both can be altered by calcineurin inhibitors,
and the disturbed balance between prostaglandins and
thromboxanes seems important in the development of
acute nephrotoxicity. It has been demonstrated in a rat
model that cyclosporine increased urinary excretion of
thromboxane B2, which correlated with reduction
in renal function, manifesting as increased serum
creatinine and decreased creatinine clearance (13). The
administration of a thromboxane synthetase inhibitor or
thromboxane receptor antagonist significantly improved
renal function compared with control rats not given these
agents (14,15). Similar studies investigating the potential
protective effects of thromboxane synthetase inhibition
in humans have yielded less conclusive results (16).
The renin-angiotensin system has been reported to have
an important role in mediating the nephrotoxic effects
of calcineurin inhibitors. It has been shown that plasma
renin activity was increased by cyclosporine, which was
associated with a decrease in kidney function and the
development of hypertension (17). Increased production
Figure 2. Renal biopsy showing striped interstitial fibrosis, a
characteristic feature of cyclosporine nephrotoxicity.
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of angiotensin II, which has potent vasoconstrictor
actions, may theoretically contribute to the acute
hemodynamic changes characteristic of acute
nephrotoxicity. However, data to date suggest that the
role of angiotensin II may be more important in the
pathogenesis of chronic nephrotoxicity. Angiotensin II
can promote fibrogenesis either directly or via the
stimulation of osteopontin (18). Angiotensin II-induced
renal fibrosis is characterized by the activation of
fibroblasts and increased synthesis of TGF-β1,
fibronectin, and type I collagen (19) (Fig. 3). Blockade
of the renin-angiotensin system with converting enzyme
inhibitor or AT-1 receptor antagonist ameliorated
cyclosporine-induced fibrosis, reduced the expression of
TGF-β1, plasminogen activator-inhibitor type 1, and
epidermal growth factor, and reduced matrix deposition
(20-22). More recently, reduced circulating levels of
TGF-β1 have been demonstrated in patients with chronic
allograft nephropathy who had been treated with losartan
(23). Although the extent of renal preservation with renin-
angiotensin blockade remains to be defined, there is
increasing evidence to support this therapeutic approach
in the management of patients with chronic allograft
nephropathy, irrespective of the relative contribution of
immunologic and nonimmunologic factors.
Endothelin is a peptide with powerful vasoconstrictor
properties. Calcineurin inhibitors stimulate the synthesis
and release of endothelin from renal cells. Endothelin
has been implicated in the acute hemodynamic changes
induced by cyclosporine. It has also been proposed that
increased endothelin may contribute toward the
development of cyclosporine nephrotoxicity via the
induction of TGF-β1 (24) (Fig. 3).
Nitric oxide is a potent vasodilator derived from multiple
cell types, and is synthesized from L-arginine by a family
of nitric oxide synthetases (NOS). Although cyclosporine
stimulates endothelial NOS mRNA expression in the
renal cortex and increases NO synthesis and release, NO-
mediated vasodilatation is impaired (25-27). These data
suggest that the activated NOS-NO pathway is
insufficient to overcome the vasoconstrictive effect of
calcineurin inhibitors. The potential involvement of NO
in chronic nephrotoxicity of calcineurin inhibitors is
suggested by the protective effect of L-arginine on
cyclosporine-induced tubulointerstitial fibrosis in animal
experiments (28).
Increased intracellular calcium concentration has been
observed with cyclosporine, which directly enhanced the
Figure 3. Proposed pathogenetic mechanisms leading to chronic cyclosporine nephrotoxicity
and/or chronic allograft nephropathy, illustrating the important roles of TGF-β1, angiotensin II,
endothelin, and other mediators.
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contractility of mesangial cells and smooth muscle cells.
In addition, intracellular calcium may act as an indirect
mediator potentiating the effects of other endogenous
vasoconstrictors, resulting in intrarenal vasoconstriction.
The use of a calcium antagonist has been shown to offer
some protection against cyclosporine nephrotoxicity (29,
30), but these studies have not demonstrated definite
benefit on graft function and survival (31).
Oxidative stress leading to free-radical production has
been shown to be involved in the acute nephrotoxicity
of cyclosporine (32,33). This has led to interest in the
use of antioxidants in the prevention of cyclosporine
nephrotoxicity. In a rat model, N-acetylcysteine was
shown to significantly protect animals against
cyclosporine-induced renal structural and functional
impairment (34). Similarly, lazaroid antioxidant has been
reported to attenuate the acute microvascular constriction
in rat hydronephrotic kidneys upon exposure to
cyclosporine (35).
Cyclosporine enhances the activity of the sympathetic
nervous system. Upregulation of the arterial baroreflex
by cyclosporine has been demonstrated in animal
experiments (36). Direct afferent arteriolar constriction
mediated by the sympathetic nervous system has been
observed with cyclosporine use (37). Although the renal
allograft is a denervated organ, it remains possible that
denervation hypersensitivity of nerve endings or
regeneration of renal innervation may have a role if the
sympathetic nervous system is involved in acute
calcineurin inhibitor-induced nephrotoxicity.
At the cellular level, the nephrotoxic effects of
cyclosporine may be related to its differential actions in
the cytosol and mitochondria. Different subtypes of
cyclophilin have been described: cyclophilin A is found
in the cytosol, cyclophilin B in the mitochondrial
intermembranous space, and cyclophilin D in the
mitochondrial matrix. It has been proposed that binding
of cyclosporine to cytosolic cyclophilin A in T
lymphocytes accounts for the immunosuppressive
effects, whereas binding to cyclophilin B and D in kidney
cells may be responsible for the nephrotoxic effects (38).
Pathogenetic mechanisms involved in chronic
nephrotoxicity of calcineurin inhibitors are less well
defined. Drug-induced nephrotoxicity, ongoing
immunologically mediated tissue destruction and
scarring, and nonimmunologic factors such as
hypertension and hyperlipidemia, are all important
confounding variables that culminate in chronic allograft
nephropathy. The poor correlation with cumulative drug
dose underscores the multifactorial etiology. Patients
usually present with progressive deterioration in renal
function and proteinuria, but the relationship between
functional manifestations and morphological lesions is
difficult to delineate. Clinically relevant concentrations
of cyclosporine have been reported to exert a direct toxic
effect on proximal renal tubular epithelial cells, and
promote fibrogenesis by stimulating autocrine secretion
of insulin-like growth factor-I by cortical fibroblasts as
well as paracrine secretion of TGF-β1 by proximal
tubular epithelia (39). Excessive induction of TGF-β1
and tissue fibrosis are cardinal features in both
calcineurin inhibitor-induced chronic nephrotoxicity and
chronic allograft nephropathy (40,41). Both cyclosporine
and tacrolimus up-regulate the production of TGF-β1, -
β2, and -β3 (42). Anti-TGF antibody has been shown to
reduce cyclosporine-induced chronic changes in the
kidney in an animal model (43), which suggests that
TGF-β1 has a pivotal role in pathogenesis. In this regard,
TGF-β1 upregulates matrix protein and collagen
synthesis, decreases the synthesis of proteases, and
stimulates protease inhibitors such as plasminogen
activator-inhibitor type 1, thereby promoting the
deposition and inhibiting the degradation of fibrous tissue
(44). TGF-β also increases renal sympathetic activity and
the production of endothelin-1, and inhibits the synthesis
of inducible NOS (45) and renin (46). More recently,
cyclosporine has been demonstrated to stimulate the
expression of vascular endothelial growth factor in rats
placed on a low salt diet (47), and a complex inter-
relationship has been demonstrated between profibrotic
growth factors and the renin-angiotensin system (8,9,l8,
19,22,47) (Fig. 3). It has been proposed that tacrolimus
might have a lower fibrogenic potential compared with
cyclosporine, based on the finding that tacrolimus
administration resulted in less induction of TGF-β and
tissue inhibitor of metalloproteinase-1 in a rat model of
renal ischemia-reperfusion injury (48). Whether such
differences can apply to humans remains obscure, as is
the long-term graft survival in patients treated with
tacrolimus.
Management of nephrotoxicity induced
by calcineurin inhibitors
In view of the correlation between acute nephrotoxicity
and circulating blood levels of calcineurin inhibitors,
drug level monitoring is a useful means to prevent this
complication (49). Particular caution needs to be
exercised in patients treated with inhibitors of hepatic
cytochrome P450 such as diltiazem, verapamil,
fluconazole, ketoconazole, macrolide antibiotics,
fluoroquinolones, or oral contraceptives; and in patients
with fluctuating liver function, for example caused by
chronic active hepatitis B or C. In addition, increased
nephrotoxicity is to be expected in patients receiving
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concomitant treatment with aminoglycosides,
amphotericin B, and nonsteroidal anti-inflammatory
agents. Once chronic nephrotoxicity or chronic allograft
nephropathy is recognized, it is appropriate to reduce
the dose of calcineurin inhibitors to target at the lower
end of the desired circulating level (50). In this regard,
data from recent studies on C2 monitoring of
cyclosporine blood level suggest that the drug dosage
can be reduced in a significant proportion of long-term
stable patients without adverse consequences (51). The
addition of newer immunosuppressive agents such as
mycophenolate mofetil or rapamycin can be considered
when attempting to completely withdraw calcineurin
inhibitors from an individual patient. Promising results
have been observed with the latter approach, although it
may not be easy to delineate to what extent the
subsequent improvement in renal function is attributable
to reduced dose of calcineurin inhibitors or to these newer
immunosuppressive agents. Optimal control of blood
pressure, and to a lesser extent hyperlipidemia, assumes
critical importance in the long-term preservation of renal
function in patients with chronic nephrotoxicity or
chronic allograft nephropathy. Blockade of the renin-
angiotensin system may confer benefits with regard to
the amelioration of matrix deposition and fibrosis, in
additional to its effect on blood pressure control (8,9,18,
19,47).
Other immunosuppressive agents in
renal transplantation
Despite the advent of new immunosuppressive agents,
corticosteroids are still important in the prophylaxis
against rejection after renal transplantation. Although
corticosteroids have various side effects, they are free of
renal toxicity. Similarly, azathioprine and mycophenolate
mofetil have not been associated with nephrotoxicity.
Indeed, there is evidence from in vitro and animal
experiments to suggest that mycophenolate mofetil might
decrease the risk or progression of chronic allograft
nephropathy through its antiproliferative effect on
smooth muscle cells and its inhibitory actions on fibrosis
(52-55).
Rapamycin (Sirolimus) is a macrocyclic lactone
produced by Streptomyces hygroscopicus, which acts by
binding to the intracellular protein FKBP 25 to create a
complex that inhibits the target of rapamycin, a kinase
involved in signal transduction pathways triggered by
IL-2 or IL-6, thereby interfering with the progression of
T lymphocytes from the G1 to the S phase of the cell
cycle (56). Hypomagnesemia caused by increased tubular
excretion is often observed with the use of rapamycin,
otherwise the drug per se is not nephrotoxic (57).
However, caution should be exercised when rapamycin
is used together with a calcineurin inhibitor, because
enhanced nephrotoxicity has been reported (58).
Alternative strategies with early cyclosporine withdrawal
in a rapamycin-cyclosporine-based regimen have been
advocated with beneficial effects on renal function and
prevention of nephrotoxicity (59). There is also
preliminary evidence that rapamycin may be of benefit
in patients with chronic allograft nephropathy or
established chronic nephrotoxicity induced by
calcineurin inhibitors, in view of the ability of rapamycin
to inhibit growth factor-driven proliferation of
endothelial and smooth muscle cells in vitro and to disrupt
signal transduction of cytokines such as epidermal growth
factor and PDGE, which have been implicated in the
development of chronic allograft nephropathy (60,61).
Monoclonal (anti-CD3) and polyclonal (antithymocyte
globulin or antilymphocyte globulin) anti-T lymphocyte
antibodies have been used as induction therapy,
especially in highly sensitized individuals, and as
treatment for acute steroid-resistant rejection (62-64).
They have also been used for treatment of steroid-
resistant acute rejection (64). Initial doses of these
antibody preparations may induce a massive release of
vasoactive substances including prostaglandins, tumor
necrosis factor-α, and IL-6 (65), resulting in fever,
diarrhea, pulmonary edema, and indirectly leading to
acute renal failure. Prevention is by prophylactic
administration of corticosteroid and antihistamine. These
manifestations usually become less severe with
subsequent doses.
The administration of IL-2 receptor antagonists has not
been associated with any nephrotoxicity. The clinical role
and the side-effects profile of new immunosuppressive
agents such as CTLA-4 immunoglobulin, anti-CD40
ligand, brequinar, leflunomide, and deoxyspergualin are
being investigated.
CONCLUSION
The prevention of acute renal allograft rejection has
achieved significant success in the past two decades, with
consequent improvement in short-term allograft survival.
Much of this improvement can be attributed to
calcineurin inhibitors, which have assumed a pivotal role
in the prophylactic immunosuppressive treatment in the
majority of patients. Although acute nephrotoxicity of
calcineurin inhibitors seems largely reversible and
preventable by careful attention to circulating drug levels,
the evolution of chronic nephrotoxicity induced by
calcineurin inhibitors, and its role in chronic allograft
nephropathy, are still being investigated. With the advent
of new and effective immunosuppressive agents, there
is a trend toward reduced dosage and target blood levels
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of calcineurin inhibitors, or their total avoidance in
patients with compromised renal allograft function.
Although this approach is likely to retard the deterioration
of renal function, therapeutic interventions that might
potentially reverse the morphological abnormalities
associated with chronic nephrotoxicity or chronic
allograft nephropathy remain to be established. The
addition of mycophenolate mofetil or rapamycin has
reduced the reliance on calcineurin inhibitors. Whether
these agents might be able to prevent the deleterious long-
term pathological changes remains to be investigated. It
is likely that immunosuppressive treatment after renal
transplantation will be increasingly individualized to
maximize the benefit and minimize adverse effects
pertinent to the status of allograft function and the
comorbidities in an individual patient.
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